Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approvalAlberto Martini, Colin P. Dinney, Côme Tholomier et al.|Frontiers in Immunology|2023Cited by 24
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer Treated with Nadofaragene FiradenovecVikram M. Narayan, Colin P. Dinney, Seppo Ylä‐Herttuala et al.|European Urology Oncology|2024Cited by 18
The current status of gene therapy in bladder cancerCôme Tholomier, Colin P. Dinney, Alberto Martini et al.|Expert Review of Anticancer Therapy|2023Cited by 14
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.Sharada Mokkapati, David J. McConkey, Ganiraju C. Manyam et al.|Translational Oncology|2025Cited by 4
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211Giuseppe Fallara, Alberto Martini, Federico Belladelli et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 3